Menu Back toSession-7-Patient-s-Role-in-the-Regulatory-and-HTA-Process

Value, Access and Regulatory Strategy Workshop

Session 7: Relative Efficacy versus Relative Effectiveness – the Future

Session Chair(s)

François  Meyer, MD

François Meyer, MD

  • Advisor to the President, International Affairs
  • French National Authority for Health (HAS), France
  • Current challenges in the assessment of relative efficacy/effectiveness
  • The need for comparative data
  • Role of EUnetHTA moving forward
  • Cooperation between EMA and EUnetHTA: current status and perspectives


Leeza  Osipenko, PhD, MSc

Leeza Osipenko, PhD, MSc

  • Head of Scientific Advice
  • National Institute for Health and Care Excellence (NICE), United Kingdom
Kristin  Svanqvist, MPharm

Kristin Svanqvist, MPharm

  • Governmental Affairs Manager
  • Amgen, Norway
Michael  Berntgen, PhD

Michael Berntgen, PhD

  • Head of Scientific Evidence Generation
  • European Medicines Agency, Netherlands